2023
Acne accounts for an almost 2.5-fold higher proportion of dermatology visits among adult females compared to adult males in the United States: A study of the national ambulatory medical care survey from 2002–2016
Chang J, Nock M, Cohen J, Bunick C. Acne accounts for an almost 2.5-fold higher proportion of dermatology visits among adult females compared to adult males in the United States: A study of the national ambulatory medical care survey from 2002–2016. PLOS ONE 2023, 18: e0290763. PMID: 37733776, PMCID: PMC10513303, DOI: 10.1371/journal.pone.0290763.Peer-Reviewed Original ResearchConceptsTetracycline-class antibioticsDermatology visitsAdult acnePrescribed therapyNational Ambulatory Medical Care Survey dataNational Ambulatory Medical Care SurveyAge groupsAmbulatory Medical Care SurveyAdult female acneRetrospective database analysisEffectiveness of therapyAdult age groupsFemale acneJuvenile acneAdult female populationHealthcare utilizationHigher proportionDifferent pathogenesisCare SurveyAcne vulgarisAdult malesAcneAge 20Female populationDifferent presentations
2022
Sarecycline Demonstrates Clinical Effectiveness against Staphylococcal Infections and Inflammatory Dermatoses: Evidence for Improving Antibiotic Stewardship in Dermatology
Grada A, Ghannoum MA, Bunick CG. Sarecycline Demonstrates Clinical Effectiveness against Staphylococcal Infections and Inflammatory Dermatoses: Evidence for Improving Antibiotic Stewardship in Dermatology. Antibiotics 2022, 11: 722. PMID: 35740129, PMCID: PMC9220064, DOI: 10.3390/antibiotics11060722.Peer-Reviewed Original ResearchBroad-spectrum tetracyclineInflammatory dermatosesAntibiotic stewardshipStaphylococcal infectionsClinical effectivenessSkin diseasesCutaneous staphylococcal infectionsReported adverse eventsFirst-line agentsInflammatory skin diseaseMucous membrane pemphigoidAnti-inflammatory propertiesStaphylococcal skin infectionsAntibiotic resistanceTetracycline-class antibioticsAdverse eventsAcne rosaceaClinical findingsCutaneous infectionsAcne vulgarisSkin infectionsMedicine careStrong rationaleInfectionMultiple skin diseasesSarecycline Demonstrated Reduced Activity Compared to Minocycline against Microbial Species Representing Human Gastrointestinal Microbiota
Ghannoum MA, Long L, Bunick CG, Del Rosso JQ, Gamal A, Tyring SK, McCormick TS, Grada A. Sarecycline Demonstrated Reduced Activity Compared to Minocycline against Microbial Species Representing Human Gastrointestinal Microbiota. Antibiotics 2022, 11: 324. PMID: 35326788, PMCID: PMC8944611, DOI: 10.3390/antibiotics11030324.Peer-Reviewed Original ResearchMinimum inhibitory concentrationVitro minimum inhibitory concentrationHigh minimum inhibitory concentrationsTetracycline-class antibioticsTime-kill assaysBroad-spectrum tetracycline antibioticTime-kill kinetic assayGastrointestinal tract microbiotaHigh MIC valuesHuman gastrointestinal microbiotaLess activityAcne treatmentGut microbiotaMinocyclineGut microbiomeGastrointestinal microbiotaSarecyclineInhibitory concentrationGut microorganismsSkin microbiomeVivo testingReduced activityMicrobiotaMIC valuesAntibiotics
2021
Sarecycline treatment for acne vulgaris: Rationale for weight‐based dosing and limited impact of food intake on clinical efficacy
Grada A, Del Rosso JQ, Graber E, Bunick CG, Gold L, Moore AY, Baldwin H, Obagi Z, Damiani G, Carrothers T, McNamee B, Hanze E. Sarecycline treatment for acne vulgaris: Rationale for weight‐based dosing and limited impact of food intake on clinical efficacy. Dermatologic Therapy 2021, 35: e15275. PMID: 34923732, PMCID: PMC9286649, DOI: 10.1111/dth.15275.Peer-Reviewed Original ResearchConceptsTetracycline-class antibioticsWeight-based dosingHigh-fat mealClinical efficacyAcne vulgarisFood intakeWeight-based dosing protocolAcne vulgaris patientsLow clinical efficacyExposure-response modelingPopulation pharmacokinetic modelingAcne vulgaris treatmentHigh-fat foodsDosing protocolDosing recommendationsInflammatory lesionsVulgaris patientsExtent of exposureClinical studiesImproved complianceGastrointestinal absorptionVulgaris treatmentDrug AdministrationPharmacokinetic modelingEfficacyAntibacterial Mechanisms and Efficacy of Sarecycline in Animal Models of Infection and Inflammation
Bunick CG, Keri J, Tanaka SK, Furey N, Damiani G, Johnson JL, Grada A. Antibacterial Mechanisms and Efficacy of Sarecycline in Animal Models of Infection and Inflammation. Antibiotics 2021, 10: 439. PMID: 33920812, PMCID: PMC8071131, DOI: 10.3390/antibiotics10040439.Peer-Reviewed Original ResearchTetracycline-class antibioticsBroad-spectrum antibiotic useRat paw edema modelPaw edema modelAnti-inflammatory activityWound infection modelSevere acneEdema modelPatient outcomesAntibiotic useMurine modelAnimal modelsDrug AdministrationGut microfloraInfection modelSarecyclineVivo studiesRelevant Gram-positive bacteriaReduced efficacyInfectionAntimicrobial resistanceVivo activityAntibiotic resistanceInflammationReduced activity